United Therapeutics (NASDAQ:UTHR) CEO Sells $5,048,110.00 in Stock

Posted by Stanley Muller on Aug 10th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $531.38, for a total value of $5,048,110.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $172,402,521.34. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Down 1.7%

NASDAQ:UTHR traded down $9.18 during midday trading on Monday, reaching $529.66. The stock had a trading volume of 394,230 shares, compared to its average volume of 494,128. United Therapeutics Corporation has a 12-month low of $292.34 and a 12-month high of $609.35. The stock has a market cap of $22.72 billion, a P/E ratio of 18.95, a P/E/G ratio of 1.82 and a beta of 0.59. The firm has a fifty day simple moving average of $539.43 and a two-hundred day simple moving average of $534.71.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the previous year, the firm earned $6.41 earnings per share. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on UTHR. JPMorgan Chase & Co. boosted their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a report on Thursday. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Royal Bank Of Canada dropped their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, July 31st. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

View Our Latest Research Report on United Therapeutics

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of UTHR. BlackRock Inc. acquired a new stake in United Therapeutics in the second quarter valued at $2,868,735,000. Wellington Management Group LLP lifted its holdings in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. Norges Bank acquired a new position in United Therapeutics during the 4th quarter valued at approximately $293,418,000. Avoro Capital Advisors LLC boosted its holdings in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.